Changes in imatinib plasma trough level during long-term treatment in patients with intermediate- or high-risk gastrointestinal stromal tumors: Relationship between covariates and imatinib plasma trough level

BACKGROUND: Imatinib is the first-line adjuvant treatment for gastrointestinal stromal tumors (GISTs). Considering that some studies have suggested that imatinib (IM) plasma trough levels (C(min)) change with time, the aim of this study is to assess the changes in IM C(min) in patients with GIST in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xingye, Ge, Yinggang, He, Xuemei, Li, Juan, Zhang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Surgery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995696/
https://www.ncbi.nlm.nih.gov/pubmed/36911619
http://dx.doi.org/10.3389/fsurg.2023.1115141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995696/
https://www.ncbi.nlm.nih.gov/pubmed/36911619
http://dx.doi.org/10.3389/fsurg.2023.1115141

Ejemplares similares